Royce & Associates LP maintained its position in shares of Kindred Biosciences, Inc. (NASDAQ:KIN) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 126,000 shares of the biopharmaceutical company’s stock at the close of the 2nd quarter. Royce & Associates LP owned 0.54% of Kindred Biosciences worth $1,084,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in KIN. Trexquant Investment LP bought a new stake in Kindred Biosciences during the 2nd quarter worth approximately $120,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in Kindred Biosciences during the 1st quarter worth approximately $102,000. State of Wisconsin Investment Board bought a new stake in Kindred Biosciences during the 2nd quarter worth approximately $129,000. Goldman Sachs Group Inc. grew its position in Kindred Biosciences by 28.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 22,336 shares of the biopharmaceutical company’s stock worth $157,000 after acquiring an additional 4,954 shares during the last quarter. Finally, Rhumbline Advisers bought a new stake in Kindred Biosciences during the 2nd quarter worth approximately $197,000. Institutional investors own 60.37% of the company’s stock.

A number of research firms recently commented on KIN. Zacks Investment Research lowered Kindred Biosciences from a “buy” rating to a “hold” rating and set a $8.50 price target on the stock. in a research report on Tuesday. Aegis began coverage on Kindred Biosciences in a research report on Friday, June 16th. They set a “buy” rating and a $10.50 price target on the stock. ValuEngine upgraded Kindred Biosciences from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Finally, FBR & Co restated a “buy” rating on shares of Kindred Biosciences in a research report on Wednesday, May 31st. Three analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. Kindred Biosciences presently has an average rating of “Buy” and a consensus target price of $8.90.

WARNING: “Royce & Associates LP Maintains Holdings in Kindred Biosciences, Inc. (KIN)” was posted by Daily Political and is owned by of Daily Political. If you are accessing this article on another domain, it was illegally copied and republished in violation of international trademark & copyright law. The legal version of this article can be accessed at https://www.dailypolitical.com/2017/09/16/royce-associates-lp-maintains-holdings-in-kindred-biosciences-inc-kin.html.

In other news, major shareholder Park West Asset Management Llc acquired 600,000 shares of the stock in a transaction on Wednesday, July 12th. The stock was acquired at an average cost of $7.50 per share, for a total transaction of $4,500,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Richard Chin sold 13,000 shares of the business’s stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $8.26, for a total transaction of $107,380.00. Following the transaction, the insider now owns 2,297,546 shares of the company’s stock, valued at $18,977,729.96. The disclosure for this sale can be found here. 19.10% of the stock is owned by insiders.

Shares of Kindred Biosciences, Inc. (NASDAQ:KIN) opened at 7.40 on Friday. Kindred Biosciences, Inc. has a 52-week low of $3.90 and a 52-week high of $9.65. The company’s market capitalization is $205.99 million. The company’s 50-day moving average price is $7.27 and its 200-day moving average price is $7.19.

Kindred Biosciences (NASDAQ:KIN) last announced its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.04. Equities research analysts forecast that Kindred Biosciences, Inc. will post ($1.27) EPS for the current fiscal year.

About Kindred Biosciences

Kindred Biosciences, Inc is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products.

Want to see what other hedge funds are holding KIN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kindred Biosciences, Inc. (NASDAQ:KIN).

Institutional Ownership by Quarter for Kindred Biosciences (NASDAQ:KIN)

Receive News & Ratings for Kindred Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.